Scientific and corporate news
Stem cell secretome from adipose tissue as a biotherapeutic agent to inhibit growth of triple-negative breast cancer
n this experimental study, a protocol was developed for processing a formulation derived from secretome obtained from adipose tissue mesenchymal stem cells at different concentrations. Its molecular composition and in vitro efficacy was evaluated when applied to breast cancer cell lines. In addition, the ability of the formulation to suppress the growth of triple-negative breast cancer when infused into a mouse model of the disease was verified.
Current therapies do not induce significant benefits in chronic stroke patients. Preclinical studies suggest that autologous transplantation of adipose tissue stem cells may be of benefit. This phase one clinical trial was developed to test the safety and efficacy of adipose tissue mesenchymal stem transplantation in chronic stroke patients.
Outcomes of adipose tissue stem cell transplantation for the treatment of refractory lupus nephritis
To date, the immunomodulatory capacity of mesenchymal stem cells is well known. In this phase one clinical trial, the efficacy of these cells for the treatment of refractory lupus nephritis (LN) was verified. Specifically, 9 patients received systemic infusion of mesenchymal stem cells derived from adipose tissue and followed up for a 12-month follow-up period.
Outcomes of mesenchymal stem cell transplantation from umbilical cord for the treatment of decompensated liver cirrhosis
group (n = 111) and cord blood mesenchymal stem cell infusion group (n = 108). Both groups were followed up for a follow-up period of 7 years (October 2010 to October 2017). Specifically, patients in the control group received only conventional therapy while patients in the other group received three infusions of mesenchymal stem cells from cord tissue at four-week intervals.